Regulating transcription factor RUNX1 using small molecule drugs a promising novel therapy for diseases of the retina, including advanced diabetic eye disease.
Yoshihiro Yonekawa, MD, was included in The Ophthalmologist’s 2017 Power List. This list is created by the magazine’s leadership, who vote for ophthalmology’s top 50 rising stars. Dr. Yonekawa joined...
Boston, Mass. — The brains of those who are born blind make new connections in the absence of visual information, resulting in enhanced, compensatory abilities such as a heightened sense of hearing...
Five Ophthalmology residents have been selected for 2017-2018 Heed fellowships by the Heed Ophthalmic Foundation and the Society of Heed Fellows. This accounts for nearly 25% of of all awarded Heed...
